Business
OWC Pharmaceutical Research Corp. Announces Special Meeting of Stockholders
OWC Pharmaceutical Research Corp. Announces Special Meeting of Stockholders.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp. Announces Special Meeting of Stockholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOWC Pharmaceutical Research Corp. Announces Special Meeting of Stockholders\nMeeting tentatively scheduled for August 25, 2020\nThe USPTO recently awarded the company a patent for its Cannabis-based Extracts and Topicals for Skin Disorder.\nOWC engaged Stanley Wunderlich, CEO, Consulting for Strategic Growth1, Ltd. for IR/PR representation\nPR Newswire\nPETACH TIKVA, Israel, July 29, 2020\n\n\n\nPETACH TIKVA, Israel, July 29, 2020 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTC: OWCP) (\"OWC\"), announced that it will be holding a special meeting of stockholders to vote on a reverse stock split (the \"Reverse Split\") at a ratio between 1:10 and 1:20 as outlined in the company's recently filed proxy statement.  The meeting is tentatively scheduled for August 25, 2020.\n\n \n \n \n \n \n \n\n \nMr. Ziv Turner, Chairman and CEO comments: \"Through the  company's unique and innovative products, which are supported by clinical studies and results, OWC is poised to drive significant changes in the MMJ market. Our top priorities now are to generate revenues by selling those products and seeking strategic partners or transactions with participants in the US cannabis market - currently the largest MMJ market in the world. In order to achieve these goals we need to raise funds from new investors. With no authorized share capital available, the Reverse Split is a critical move for us.\" \n\"We have developed a roadmap for the next two years and will provide a description in the near future\", added Turner. \"Without approval of the Reverse Split by our shareholders, we will likely be unable to secure the needed investment to execute on the roadmap.\"\nTurner continues: \"On March 31, 2020, the USPTO issued a patent for our Cannabis-Based Extracts and Topical Formulations for use in Skin Disorders, no. US 10.603.301 B2. This is the only cannabis-infused and cannabis-based topical known to us that is the subject of an issued patent by t...